Assunta Senatore

Assunta Senatore

Auto-generated profile, based on publicly available information

Assunta Senatore

Institute of Neuropathology University Hospital of Zurich Zurich Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Neuron
Verified
Journal Article
Open access
PDF file
ASAssunta Senatore
Assunta Senatore
SCSimona Colleoni
Simona Colleoni
CFChiara Fenoglio
Chiara Fenoglio
Elena RestelliElena Restelli
Elena Restelli
RMRaffaella Morini
Raffaella Morini
RCRoberto Chiesa
Roberto Chiesa
How mutant prion protein (PrP) leads to neurological dysfunction in genetic prion diseases is unknown. Tg(PG14) mice synthesize a misfolded mutant PrP which is partially retained in the neuronal endoplasmic reticulum (ER). As these mice age, they develop ataxia and massive degeneration of cerebellar granule neurons (CGNs). Here, we report that motor behavioral deficits in Tg(PG14) mice emerge before neurodegeneration and are associated with defective glutamate exocytosis from granule neurons due to impaired calcium dynamics. We found that mutant PrP interacts with the voltage-gated calcium channel α2δ-1 subunit, which promotes the anterograde trafficking of the channel. Owing to ER retention of mutant PrP, α2δ-1 accumulates intracellularly, impairing delivery of the channel complex to the cell surface. Thus, mutant PrP disrupts cerebellar glutamatergic neurotransmission by reducing the number of functional channels in CGNs. These results link intracellular PrP retention to synaptic dysfunction, indicating new modalities of neurotoxicity and potential therapeutic strategies.

27 November 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DGDespoina Goniotaki
Despoina Goniotaki
ALAsvin K K Lakkaraju
Asvin K K Lakkaraju
ASAmulya N Shrivastava
Amulya N Shrivastava
PBPamela Bakirci
Pamela Bakirci
SSSilvia Sorce
Silvia Sorce
AAAdriano Aguzzi
Adriano Aguzzi
Prion infections cause inexorable, progressive neurological dysfunction and neurodegeneration. Expression of the cellular prion protein PrPC is required for toxicity, suggesting the existence of deleterious PrPC-dependent signaling cascades. Because group-I metabotropic glutamate receptors (mGluR1 and mGluR5) can form complexes with the cellular prion protein (PrPC), we investigated the impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We found that pharmacological inhibition of mGluR1 and mGluR5 antagonized dose-dependently the neurotoxicity triggered by prion infection and by prion-mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increased mGluR5 clustering around dendritic spines, mimicking the toxicity of Aβ oligomers. Oral treatment with the mGluR5 inhibitor, MPEP, delayed the onset of motor deficits and moderately prolonged survival of prion-infected mice. Although group-I mGluR inhibition was not curative, these results suggest that it may alleviate the neurological dysfunctions induced by prion diseases. Prion diseases are a result of ordered accumulation of the misfolded conformer of cellular prion protein (PrPC), a GPI anchored protein expressed on the cell surface. Similar pathogenetic principles operate in several other neurodegenerative diseases. Currently no disease-modifying therapies exist and the situation is compounded by a dearth of validated therapeutic targets. In our present study, we have discovered that genetic ablation, or pharmacological inhibition, of group-I (i.e. activating) metabotropic glutamate receptors is beneficial against prion neurotoxicity in vitro and in vivo. Mice treated with these inhibitors exhibited impressive suppression of neurological signs and a delayed onset of the symptoms. These results further suggest that activation of these metabotropic glutamate receptors is a downstream event of prion replication and targeting these receptors could be a therapeutic option to alleviate the neurological symptoms, thereby ameliorating the quality of life in patients having prion infection.

17 February 2022 in Brain Pathology
Verified
Journal Article
Open access
PDF file
ALAsvin K. K. Lakkaraju
Asvin K. K. Lakkaraju
SSSilvia Sorce
Silvia Sorce
ASAssunta Senatore
Assunta Senatore
MNMario Nuvolone
Mario Nuvolone
JGJingjing Guo
Jingjing Guo
AAAdriano Aguzzi
Adriano Aguzzi
Although prion infections cause cognitive impairment and neuronal death, transcriptional and translational profiling shows progressive derangement within glia but surprisingly little changes within neurons. Here we expressed PrPC selectively in neurons and astrocytes of mice. After prion infection, both astrocyte and neuron‐restricted PrPC expression led to copious brain accumulation of PrPSc. As expected, neuron‐restricted expression was associated with typical prion disease. However, mice with astrocyte‐restricted PrPC expression experienced a normal life span, did not develop clinical disease, and did not show astro‐ or microgliosis. Besides confirming that PrPSc is innocuous to PrPC‐deficient neurons, these results show that astrocyte‐born PrPSc does not activate the extreme neuroinflammation that accompanies the onset of prion disease and precedes any molecular changes of neurons. This points to a nonautonomous mechanism by which prion‐infected neurons instruct astrocytes and microglia to acquire a specific cellular state that, in turn, drives neural dysfunction.

10 August 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ASAssunta Senatore
Assunta Senatore
KFKarl Frontzek
Karl Frontzek
MEMarc Emmenegger
Marc Emmenegger
ACAndra Chincisan
Andra Chincisan
MLMarco Losa
Marco Losa
AAAdriano Aguzzi
Adriano Aguzzi
Prion immunotherapy may hold great potential, but antibodies against certain PrP epitopes can be neurotoxic. Here, we identified > 6,000 PrP‐binding antibodies in a synthetic human Fab phage display library, 49 of which we characterized in detail. Antibodies directed against the flexible tail of PrP conferred neuroprotection against infectious prions. We then mined published repertoires of circulating B cells from healthy humans and found antibodies similar to the protective phage‐derived antibodies. When expressed recombinantly, these antibodies exhibited anti‐PrP reactivity. Furthermore, we surveyed 48,718 samples from 37,894 hospital patients for the presence of anti‐PrP IgGs and found 21 high‐titer individuals. The clinical files of these individuals did not reveal any enrichment of specific pathologies, suggesting that anti‐PrP autoimmunity is innocuous. The existence of anti‐prion antibodies in unbiased human immunological repertoires suggests that they might clear nascent prions early in life. Combined with the reported lack of such antibodies in carriers of disease‐associated PRNP mutations, this suggests a link to the low incidence of spontaneous prion diseases in human populations.

20 September 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KFKarl Frontzek
Karl Frontzek
MBMarco Bardelli
Marco Bardelli
ASAssunta Senatore
Assunta Senatore
AHAnna Henzi
Anna Henzi
RRRegina Rose Reimann
Regina Rose Reimann
AAAdriano Aguzzi
Adriano Aguzzi
Summary: Prion infections cause conformational changes of PrP C and lead to progressive neurological impairment. Here we show that toxic, prion-mimetic ligands induce an intramolecular R208-H140 hydrogen bond (“H-latch”) altering the flexibility of the α2-α3 and β2-α2 loops of PrP C . Expression of a PrP 2Cys mutant mimicking the H-latch was constitutively toxic, whereas a PrP R207A mutant unable to form the H-latch conferred resistance to prion infection. High-affinity ligands that prevented H-latch induction repressed prion-related neurodegeneration in organotypic cerebellar cultures. We then selected phage-displayed ligands binding wild-type PrP C , but not PrP 2Cys . These binders depopulated H-latched conformers and conferred protection against prion toxicity. Finally, brain-specific expression of an antibody rationally designed to prevent H-latch formation, prolonged the life of prion-infected mice despite unhampered prion propagation, confirming that the H-latch is causally linked to prion neurotoxicity.

5 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAssunta Senatore
Assunta Senatore
KFKarl Frontzek
Karl Frontzek
MEMarc Emmenegger
Marc Emmenegger
ACAndra Chincisan
Andra Chincisan
MLMarco Losa
Marco Losa
AAAdriano Aguzzi
Adriano Aguzzi
Prion immunotherapy may hold great potential, but antibodies against certain PrP epitopes can be neurotoxic. Here we identified >6000 PrP-binding antibodies in a synthetic human Fab phage display library, 49 of which we characterized in detail. Antibodies directed against the flexible tail of PrP conferred neuroprotection against infectious prions. We then mined published repertoires of circulating B cells from healthy humans and found antibodies similar to the protective phage-derived antibodies. When expressed recombinantly, these antibodies exhibited anti-PrP reactivity. Furthermore, we surveyed 48’718 samples from 37’894 hospital patients for the presence of anti-PrP IgGs, and found 21 high-titer individuals. The clinical files of these individuals did not reveal any enrichment of specific pathologies, suggesting that anti-PrP autoimmunity is innocuous. The existence of protective anti-prion antibodies in unbiased human immunological repertoires, combined with the reported lack of such antibodies in carriers of disease-associated PRNP mutations, suggests a link to the low incidence of spontaneous prion diseases in human populations.